In Q1 FY2026, Revvity reported revenue of $711.1M, up 7.0% year-over-year. Net income was $40.7M, down 3.6% from the prior year. Operating income rose 5.1% to $75.9M, and diluted EPS increased 2.9% to $0.36. The company held $860.3M in cash, with equity of $7.2B and long-term debt of $2.6B.
•Revenue grew 7.0% YoY to $711.1M.
•Net income decreased 3.6% YoY to $40.7M.
•Operating income increased 5.1% YoY to $75.9M.
•Diluted EPS rose 2.9% YoY to $0.36.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Revvity provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services
Instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood Infectious disease testing in the diagnostics market.
Its products are used for testing and screening genetic abnormalities, disorders, and diseases Including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.
The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. Founded in 1937 and headquartered in Waltham, Massachusetts, Revvity was formerly known as PerkinElmer, Inc. before rebranding in April 2023.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers a wide range of products including instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training services. In the diagnostics market, it provides instruments, reagents, assay platforms, and software for early detection of common and rare conditions such as pregnancy, early childhood disorders, and infectious diseases. Its products are used for testing genetic abnormalities like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. Revvity also develops technologies for genomic workflows using protein-coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies.
Where is Revvity (RVTY) listed and what currency does it trade in?
Revvity, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol RVTY. The company is based in the United States and trades in US Dollars (USD). As a US-listed company, its stock is traded in the US region and follows the regulatory framework of the NYSE. Investors can buy and sell RVTY shares during regular trading hours on the NYSE, and the stock price is quoted in USD. The company's financial reports and dividends, if any, are also denominated in US Dollars.
What sector and industry does Revvity (RVTY) operate in?
Revvity, Inc. operates in the Healthcare sector and is classified under the Diagnostics & Research industry. This means the company is primarily involved in providing diagnostic tools, research services, and health sciences solutions. The Diagnostics & Research industry includes companies that develop and manufacture diagnostic tests, instruments, reagents, and software used in clinical laboratories, research institutions, and healthcare settings. Revvity's focus on early detection of diseases, genetic testing, and genomic workflows aligns with this industry. Its products support a wide range of applications from newborn screening to oncology and drug discovery, making it a key player in the healthcare diagnostics and research space.
Who are Revvity's (RVTY) main customers and what brands does it offer?
Revvity serves a diverse customer base including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company markets its products under numerous brand names such as AutoDELFIA, chemagic, DELFIA, EUROIMMUN, GSP, IDS Immunodiagnosticsystems, NEXTFLEX, Panthera Puncher, T-SPOT, Vanadis, and ViaCord, among others. These brands cover a wide range of applications from immunoassays and molecular diagnostics to newborn screening and genomic analysis. For example, the T-SPOT brand is known for tuberculosis testing, while ViaCord focuses on cord blood banking. This extensive portfolio allows Revvity to address various needs in diagnostics, research, and clinical testing.
What is Revvity's (RVTY) business model and how does it generate revenue?
Revvity generates revenue through the sale of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training, and services. The company's business model combines product sales with recurring revenue streams from consumables, software subscriptions, and service contracts. For instance, its instruments like the GSP or IDS-iSYS require ongoing purchases of reagents and consumables, creating a steady revenue flow. Additionally, Revvity offers software platforms such as EUROLabWorkstation and iLab, which may be sold via subscriptions or licenses. The company also provides extended warranties and training services, adding to its service-based income. By serving a broad range of customers in pharmaceutical, biotechnology, academic, and government sectors, Revvity diversifies its revenue sources across different geographic and market segments.